Stay updated with breaking news from Evofem Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brokerages expect that Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) will post $4.23 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Evofem Biosciences’ earnings. The highest sales estimate is $5.30 million and the lowest is $3.30 million. Evofem Biosciences posted sales of $1.11 million during the […]
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the Journal of Sexual Medicine, a peer-reviewed medical journal, published data...
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Karina Fedasz as its Head of Business Development. At Evofem,...
/PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) ("Evofem" and the "Company"), a commercial-stage biopharmaceutical company, today announced the Nasdaq...
Phase 2B/3 AMPREVENCE Clinical Trial Concluded with Women Experiencing a 50 Percent Risk Reduction in Chlamydia Trachomatis (chlamydia) and a 78 Percent Risk...